4538.T
Fuso Pharmaceutical Industries,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 2,272.00
−0.61%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 62.3B | 62.3B | 60.6B | 55.4B | 51.0B |
| Cost of Revenue | 11.4B | 46.3B | 44.0B | 41.6B | 37.3B |
| Gross Profit | 4.1B | 16.0B | 16.5B | 13.8B | 13.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 3.5B | 13.4B | 12.4B | 11.9B | 11.5B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.5B | 13.4B | 12.4B | 11.9B | 11.5B |
| Cost and Expenses | 59.7B | 59.7B | 56.4B | 53.4B | 48.8B |
| Operating Income (EBIT) | 2.6B | 2.6B | 4.1B | 2.0B | 2.2B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 70.0M | 328.0M | 161.0M | 171.0M | 165.0M |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 50.0M | (290.0M) | (351.0M) | (96.0M) | 10.0M |
| Non-Operating Income (excl Interest) | 11.0M | 46.0M | 44.0M | 55.0M | 79.0M |
| EBT (Pre-Tax Income) | 647.0M | 2.4B | (5.0B) | 1.8B | 2.2B |
| Income Tax Expense | 184.0M | 426.0M | (1.7B) | 389.0M | 599.0M |
| Bottom Line | |||||
| Net Income | 2.0B | 2.0B | (3.3B) | 1.4B | 1.6B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.0B | 2.0B | (3.3B) | 1.4B | 1.6B |
| Per Share | |||||
| Basic EPS | ¥236 | ¥236 | (¥385) | ¥160 | ¥183 |
| Diluted EPS | ¥236 | ¥236 | — | — | — |
| Revenue Per Share | ¥7,297 | ¥7,297 | ¥7,090 | ¥6,435 | ¥5,816 |
| Shares | |||||
| Basic Shares Outstanding | 8.5M | 8.5M | 8.5M | 8.6M | 8.8M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 5.3B | 6.5B | 4.2B | 4.7B |
| D&A | — | 2.6B | 2.4B | 2.3B | 2.5B |
| EBIT | 2.6B | 2.6B | 4.1B | 2.0B | 2.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026